Figure 6. NEAT 1 knockdown enhances the anti-tumor effect of anlotinib in vivo. To form subcutaneous tumors, 5 × 106 A549 cells were injected subcutaneously into the right flank of each mouse. After the tumor volume reached 180 mm3, the mice were treated with anlotinib or anlotinib+NEAT1 siRNA3. (A) Tumor volume was measured at week 0, 1, 2, 3, and 4. (B) Mice were sacrificed at week 4 after treatment. Tumors were harvested and imaged. (C) Tumor weight was evaluated. (D) Calculated tumor weight inhibitory rates. (E) The expression of NEAT1 in tumor tissues was detected with RT-qPCR. **P < 0.01 compared with the control group. ##P < 0.01, compared with the anlotinib group.